Compare VTSI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTSI | MAIA |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9M | 44.9M |
| IPO Year | N/A | 2022 |
| Metric | VTSI | MAIA |
|---|---|---|
| Price | $4.25 | $1.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 51.2K | ★ 1.0M |
| Earning Date | 11-10-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $24,934,267.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.39 | N/A |
| P/E Ratio | $299.15 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.57 | $0.87 |
| 52 Week High | $7.47 | $2.74 |
| Indicator | VTSI | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 32.24 | 55.23 |
| Support Level | $4.32 | $1.13 |
| Resistance Level | $4.45 | $1.64 |
| Average True Range (ATR) | 0.15 | 0.16 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 10.56 | 45.16 |
VirTra Inc is a U.S.-based company that is engaged in the sale and development of the judgmental use of force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company sells and supports the use of force training and marksmanship firearms training systems and accessories for law enforcement, military, or civilian use. Company's The product lany includes simulators, upgrade components, scenarios, scenario software, recoil kits, Threat Fire, and other accessories.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.